Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: Involvement of CYP1A2-mediated metabolism

British Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2009, Pages 89-96

  Doki, Kosuke ^a   Homma, Masato ^a   Kuga, Keisuke ^a   Aonuma, Kazutaka ^a   Kohda, Yukinao ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Ageing; CYP1A2; CYP2D6; Flecainide; Metabolism

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; CARTEOLOL; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DIGOXIN; DILTIAZEM; DRUG METABOLITE; ENALAPRIL; FAMOTIDINE; FLECAINIDE; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; NADOLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; QUINAPRIL; RANITIDINE; TICLOPIDINE; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; CYP2D6 GENE; DRUG METABOLISM; ENZYME POLYMORPHISM; FEMALE; GENE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; FEMALE; FLECAINIDE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; TACHYCARDIA, SUPRAVENTRICULAR; YOUNG ADULT;

EID: 67650932092     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03435.x     Document Type: Article

References (27)

1. Crozier IG, Ikram H, Kenealy M, Levy L. Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm. Am J Cardiol 1987 59 : 607 9.
2. Kreeger RW, Hammill SC. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc 1987 62 : 1033 50.
3. Conard GJ, Ober RE. Metabolism of flecainide. Am J Cardiol 1984 53 : 41B 51B.
4. McQuinn RL, Quarfoth GJ, Johnson JD, Banitt EH, Pathre SV, Chang SF, Ober RE, Conard GJ. Biotransformation and elimination of 14C-flecainide acetate in humans. Drug Metab Dispos 1984 12 : 414 20.
5. Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 1989 45 : 562 7.
6. Doki K, Homma M, Kuga K, Kusano K, Watanabe S, Yamaguchi I, Kohda Y. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2006 62 : 919 26.
7. Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 1989 28 : 555 66.
8. Gross AS, Mikus G, Fischer C, Eichelbaum M. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. Eur J Clin Pharmacol 1991 40 : 155 62.
9. Birgersdotter UM, Wong W, Turgeon J, Roden DM. Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. Br J Clin Pharmacol 1992 33 : 275 80.
10. Doki K, Homma M, Kuga K, Aonuma K, Sakai S, Yamaguchi I, Kohda Y. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 2007 63 : 951 7.
11. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet 1997 33 : 302 12.
12. Kinirons MT, O'Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004 57 : 540 4.
13. Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988 44 : 431 5.
14. Pollock BG, Perel JM, Altieri LP, Kirshner M, Fasiczka AL, Houck PR, Reynolds CF III. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992 28 : 163 8.
15. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007 50 : 927 37.
16. Ishiguro A, Kubota T, Soya Y, Sasaki H, Yagyu O, Takarada Y, Iga T. High-throughput detection of multiple genetic polymorphisms influencing drug metabolism with mismatch primers in allele-specific polymerase chain reaction. Anal Biochem 2005 337 : 256 61.
17. Latini R, Cavalli A, Maggioni AP, Volpi A. Flecainide distribution in human tissues. Br J Clin Pharmacol 1987 24 : 820 2.
18. Doki K, Homma M, Kuga K, Watanabe S, Yamaguchi I, Kohda Y. Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography. J Pharm Biomed Anal 2004 35 : 1307 12.
19. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997 73 : 147 71.
20. Loi CM, Parker BM, Cusack BJ, Vestal RE. Aging and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997 280 : 627 37.
21. Chung WG, Kang JH, Park CS, Cho MH, Cha YN. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther 2000 67 : 258 66.
22. Homma M, Kuga K, Doki K, Katori K, Yamaguchi I, Sugibayashi K, Kohda Y. Assessment of serum flecainide trough levels in patients with tachyarrhythmia. J Pharm Pharmacol 2005 57 : 47 51.
23. Morganroth J, Horowitz LN. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984 53 : 89B 94B.
24. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006 166 : 719 28.
25. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001 37 : 371 8.
26. Atarashi H. Long-term study of flecainide in patients with paroxysmal atrial fibrillation or flutter. J Clin Therap Med 2007 23 : 841 57.
27. Holtzman JL, Weeks CE, Kvam DC, Berry DA, Mottonen L, Ekholm BP, Chang SF, Conard GJ. Identification of drug interactions by meta-analysis of premarketing trials: the effect of smoking on the pharmacokinetics and dosage requirements for flecainide acetate. Clin Pharmacol Ther 1989 46 : 1 8.